Spotlight on Urology
Understanding the Disease Continuum and Navigating the Evolving Treatment Paradigms in Prostate Cancer
StartActivity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Formulate individualized treatment plans for prostate cancer patients across the disease continuum by employing current standards of care for appropriate sequences and/or combinations
- Assess the latest clinical data on hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination to safely and effectively integrate them into care across the disease spectrum
- Identify ongoing clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mount Sinai Hospital
New York, NY
Conflict of Interest Policy/ Disclosure Statement
William Oh, MD is a consultant to Amgen, Astellas, Bayer, Astra-Zeneca, Genzyme-Sanofi, Janssen, CPS Diagnostics, Bellicum Pharmaceuticals, and Sema4.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Sanofi Genzyme.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Formulate individualized treatment plans for prostate cancer patients across the disease continuum by employing current standards of care for appropriate sequences and/or combinations
- Assess the latest clinical data on hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination to safely and effectively integrate them into care across the disease spectrum
- Identify ongoing clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mount Sinai Hospital
New York, NY
Conflict of Interest Policy/ Disclosure Statement
William Oh, MD is a consultant to Amgen, Astellas, Bayer, Astra-Zeneca, Genzyme-Sanofi, Janssen, CPS Diagnostics, Bellicum Pharmaceuticals, and Sema4.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Sanofi Genzyme.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Urology Presentations
Navigating the Prostate Cancer Disease Continuum - Evolving Strategies in the Management of HSPC and CRPC
StartActivity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided By
Target Audience
This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
- Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
- Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA
Conflict of Interest Policy/Disclosure Statement
Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Activity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided By
Target Audience
This activity is designed to meet the educational needs of urologists, and oncologists, as well as nurses, NPs, PAs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Evaluate the latest clinical data on efficacy, safety, and sequencing considerations for hormonal, cytotoxic, immunologic, targeted, bone-directed, and investigational therapies for patients with HSPC and CRPC
- Identify ongoing and planned clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
- Implement the latest best-practice treatment strategies for patients with HSPC and CRPC, taking into consideration current guidelines and expert recommendations when individualizing treatment plans
Activity Description
This educational activity is designed to provide the oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Sectional Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA
Conflict of Interest Policy/Disclosure Statement
Dr. Dreicer has served on advisory boards for Eisai, Janssen, Seattle Genetics, Genetech/Roche, Azuri, Astra Zeneca, Orion, and Novartis.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity has been supported by an educational grant from Astellas and Medivation, Inc., a Pfizer Company, Genomic Health, Janssen Biotech, Inc., and Sanofi Genzyme.
Disclaimer Statement/Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions About the Activity
Understanding the Disease Continuum and Navigating the Evolving Treatment Paradigms in Prostate Cancer
StartActivity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Formulate individualized treatment plans for prostate cancer patients across the disease continuum by employing current standards of care for appropriate sequences and/or combinations
- Assess the latest clinical data on hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination to safely and effectively integrate them into care across the disease spectrum
- Identify ongoing clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mount Sinai Hospital
New York, NY
Conflict of Interest Policy/ Disclosure Statement
William Oh, MD is a consultant to Amgen, Astellas, Bayer, Astra-Zeneca, Genzyme-Sanofi, Janssen, CPS Diagnostics, Bellicum Pharmaceuticals, and Sema4.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Sanofi Genzyme.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.
Contact Information for Questions about the Activity
Activity Details
1.0 Contact Hour(s)
Accredited By
Rush University Medical Center
Co-provided by
Target Audience
This activity is designed to meet the educational needs of hematologists, hematologists/oncologists, community oncologists, oncology nurses and NPs, pharmacists and other healthcare professionals involved in the treatment of patients with prostate cancer.
Learning Objectives
After completing this program, participants should be able to:
- Formulate individualized treatment plans for prostate cancer patients across the disease continuum by employing current standards of care for appropriate sequences and/or combinations
- Assess the latest clinical data on hormonal, cytotoxic, immunologic, bone-directed, molecularly targeted, and other novel therapies alone and in combination to safely and effectively integrate them into care across the disease spectrum
- Identify ongoing clinical trials for prostate cancer patients across the disease continuum and refer appropriate patients to trials with novel therapies or in combination
Activity Description
This educational activity is designed to provide the hematology/oncology care team with the latest developments and critical insights into the management of prostate cancer. This education will support the healthcare professional in his/her practice setting with the essential tools to critically evaluate efficacy, safety, clinical effectiveness and application.
Statement of Educational Need
Taking into consideration the continued evolution of therapeutic modalities and management strategies for prostate cancer along with the information burden placed on busy healthcare professionals, expert guidance and interpretation of the clinical significance of emerging clinical data will benefit those caring for patients with prostate cancer, allowing for ease of assessment and incorporation into clinical practice.
Faculty
Mount Sinai Hospital
New York, NY
Conflict of Interest Policy/ Disclosure Statement
William Oh, MD is a consultant to Amgen, Astellas, Bayer, Astra-Zeneca, Genzyme-Sanofi, Janssen, CPS Diagnostics, Bellicum Pharmaceuticals, and Sema4.
Accreditation Statement
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing nursing education credit(s).
Rush University Medical Center designates this enduring activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Instructions for Receiving Credit
In order to receive credit for participating in this program, participants must listen to the program in its entirety and then complete and submit the CE evaluation form at the conclusion of the program.
Statement of Commercial Support
This activity is supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc., Clovis Oncology Inc., and Sanofi Genzyme.
Disclaimer Statement/ Disclosure of Unlabeled Use
Rush University and Plexus Communications ensure balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, Rush University identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Rush University to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Rush University is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.